Monument Therapeutics, a leader in precision neuroscience, has announced a significant £1 million equity investment from the Forster Foundation, a charitable organization. This new funding builds on previous equity and non-dilutive investments disclosed in April 2024, and will support the clinical development of MT1988, an innovative treatment targeting cognitive symptoms of schizophrenia. Cognitive impairments associated with this mental health disorder pose a serious challenge to patients’ quality of life and represent a pressing unmet medical need.
MT1988 complements existing treatments for schizophrenia, including Cobenfy, recently developed by Karuna Therapeutics and acquired by Bristol Myers Squibb for $14 billion. This investment underscores Monument’s commitment to addressing a substantial economic burden within the healthcare system, as cognitive symptoms remain poorly managed in current treatment paradigms.
In conjunction with this funding announcement, Monument Therapeutics has welcomed two new board members. Dr. Randeep Grewal, previously a board observer representing angel investors, has been appointed as board Chair. Dr. Grewal brings a wealth of experience, including roles as Chair of Bellevue Healthcare Trust and non-executive director of several organizations. His dual background as a vascular surgeon and fund manager enhances the board’s expertise in both financial and medical domains.
David Ford, a seasoned life sciences investor and former Managing Director at Prudential Capital Group, joins as an Investor Director. Ford, who also chairs VisusNano Ltd and holds non-executive roles at Vianautis and Foresight VCT plc, expressed enthusiasm for Monument’s groundbreaking approach. “The innovative strategies to develop treatments for cognitive symptoms of schizophrenia are vital, and I look forward to contributing to the company’s clinical advancements,” he stated.
Dr. Jenny Barnett, CEO of Monument Therapeutics, expressed optimism about the new investment, noting, “The support from the Forster Foundation highlights the growing confidence in our precision neuroscience approach. This funding will bring us closer to fulfilling our mission of improving lives impacted by schizophrenia and related conditions.”
Editorial Opinion
Monument Therapeutics is at a pivotal juncture, harnessing the power of precision medicine to address the complex challenges posed by schizophrenia. The cognitive symptoms associated with this disorder remain a largely unmet need, and Monument’s innovative treatment, MT1988, promises to fill this gap effectively. By integrating digital assessments into drug development, the company is setting new standards for tailored therapeutic approaches.
The appointment of experienced leaders like Dr. Grewal and David Ford to the board is indicative of Monument’s commitment to strategic growth and innovation. Their expertise is expected to enhance the company’s trajectory as it advances its clinical programs. With the backing of the Forster Foundation and an emphasis on addressing cognitive impairments, Monument Therapeutics is poised to make significant contributions to the mental health landscape. As they move forward, the industry will be watching closely to see how their pioneering efforts can transform treatment options for patients living with schizophrenia.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
